Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT05376891
Recruiting Observational

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891 · tracked via the Priya Life Science Spain tracker
Sponsor
EMD Serono Research & Development Institute, Inc
Phase
Observational
Started
2022-10-04
Last updated
2026-10-02

Condition(s) studied

Cancer

Study summary

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants who signed ICF * Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay) * Participants who are starting or are already being treated with systemic therapy Exclusion Criteria: * Participants who are enrolled in a clinical trial

Primary outcome measure(s)

  • Best Overall Response (BOR) — Through study completion, up to approximately 4.9 years
  • Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — Up to approximately 4.9 years
  • Overall Survival (OS) — Through study completion, up to approximately 4.9 years
  • Number of Participants with Adverse Events (AEs) — Up to approximately 4.9 years
  • Number of Participants with Adverse Reactions (ARs) — Up to approximately 4.9 years

Trial sites (80)

FacilityCityRegionStatus
Holy Cross Health Fort Lauderdale Florida Recruiting
The Ohio State University Wexner Medical Center Columbus Ohio Recruiting
Vanderbilt University Medical Center Nashville Tennessee Active Not Recruiting
Klinikum Klagenfurt Am Woerthersee Klagenfurt Austria Recruiting
Landeskrankenhaus Salzburg - Universitätsklinikum der PMU Salzburg Austria Recruiting
Klinik Floridsdorf Vienna Austria Recruiting
Jessa Ziekenhuis Hasselt Belgium Recruiting
AZ Delta Roeselare Belgium Recruiting
AZ Nikolaas Sint-Niklaas Belgium Recruiting
Cliniques UCL de Mont-Godinne (7077) Yvoir Belgium Recruiting
Ottawa Hospital General Campus Ottawa Canada Recruiting
Centre Intégré de Cancérologie du CHU de Québec Québec Canada Recruiting
Princess Margaret Cancer Centre Toronto Canada Recruiting
British Columbia Cancer Agency (6864) Vancouver Canada Recruiting
FN Olomouc Olomouc Czechia Recruiting
University Hospital Na Bulovce Prague Czechia Recruiting
Centre Hospitalier de Cholet Cholet France Recruiting
CHRU Lille Lille France Recruiting
Hôpital du Scorff Lorient France Recruiting
Centre Leon Berard Lyon France Recruiting
Groupe Hospitalier Paris Saint Joseph Paris France Recruiting
Hospital Tenon & University Paris 6 Paris France Recruiting
Institut Curie - Centre de Lutte Contre le Cancer (CLCC) Paris France Recruiting
CHU de Pontchaillou Rennes France Recruiting
CHU de Toulouse Hopital Larrey Toulouse France Recruiting
Klinikum Chemnitz GmbH Chemnitz Germany Recruiting
KKH Grosshansdorf GmbH Großhansdorf Germany Recruiting
Thoraxklinik-Heidelberg gGmbH Heidelberg Germany Recruiting
Klinik Löwenstein GmbH Löwenstein Germany Recruiting
Haemek Medical Center Afula Israel Recruiting
Bnei-Zion Medical Center Haifa Israel Recruiting
Carmel Medical Center Haifa Israel Recruiting
Rambam Medical Center - PPDS Haifa Israel Recruiting
Shaare Zedek Medical Center Jerusalem Israel Recruiting
Rabin Medical Center Oncology Beilinson Campus Petah Tikva Israel Recruiting
Chaim Sheba Medical Center Ramat Gan Israel Recruiting
Tel Aviv Sourasky Medical Center Tel Aviv Israel Recruiting
Humanitas Istituto Clinico Catanese Misterbianco Sicily Recruiting
Istituto Europeo di Oncologia Milan Italy Recruiting
Istituto Nazionale Dei Tumori Milan Italy Recruiting

+ 40 more sites — see the full list on the official registry below.

More EMD Serono Research & Development Institute, Inc. trials in Spain

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Active, not recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease Recruiting
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) Active, not recruiting
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Active, not recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) Recruiting

Other trials for the same condition

Study of IMC-P115C in Advanced PRAME-Positive Cancers Recruiting
Enhancing Quality of Life in Cancer Patients Through Tailored Nutrition Support: a Comprehensive Approach Recruiting
Physiotherapy in Pediatric Oncology Starting soon
Efficacy of a Combined ACT+ App Intervention to Improve Psychological Flexibility and Associated Symptoms in Cancer Patients Active, not recruiting
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05376891 on ClinicalTrials.gov ↗ ← All trials in Spain